Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Name: Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
Published: 2023
License: Public Domain

Novartis Pharmaceuticals · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

paroxysmal nocturnal hemoglobinuria, iptacopan, single arm open-label, hb≥10 g/dl in response to anti-c5 antibody, switch to iptacopan, pnh, lnp023, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Related documents